Home | About us | Editorial board | Search | Ahead of print | Current issue | Archives | Submit article | Instructions | Subscribe | Contacts | Advertise | Login 
 
Search Article 
  
Advanced search 
  Users Online: 2604 Home Print this page Email this page Small font sizeDefault font sizeIncrease font size  

 
Table of Contents
EDITORIAL
Year : 2011  |  Volume : 15  |  Issue : 5  |  Page : 1-2

Adrenergic India: Managing its diabetes


1 Department of Endocrinology, Bharti Hospital, Karnal, Haryana, India
2 Department of Endocrinology, St. Johns Medical College, Bangalore, India
3 Department of Endocrinology, Amrita Institute of Medical Sciences, Cochin, Kerala, India

Date of Web Publication20-Jul-2011

Correspondence Address:
Ambika Gopalakrishnan Unnikrishnan
Department of Endocrinology, Amrita Institute of Medical Sciences, Cochin, Kerala
India
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/2230-8210.83046

Rights and Permissions

How to cite this article:
Kalra S, Ayyar V, Unnikrishnan AG. Adrenergic India: Managing its diabetes. Indian J Endocr Metab 2011;15, Suppl S1:1-2

How to cite this URL:
Kalra S, Ayyar V, Unnikrishnan AG. Adrenergic India: Managing its diabetes. Indian J Endocr Metab [serial online] 2011 [cited 2019 Nov 20];15, Suppl S1:1-2. Available from: http://www.ijem.in/text.asp?2011/15/5/1/83046

India is an adrenergic nation. No one can doubt this statement. While maintaining its ancient traditions, India is modernizing at a rapid rate. In every sector, ranging from agriculture to manufacturing to services, including health care, signs of progress are visible.

Health care indicators for the country convey the story of progress. Life expectancy of an average Indian has increased from 32-33 years for both genders, in 1947, to 65.77 years and, in 2011, to 67.95 years, respectively. [1],[2] The weight of the Reference Indian Man has been increased by the Indian Council for Medical Research, from 55 to 60 kg. Similarly, the Reference Indian Woman has grown heavier by 10 kg, and weighs 55 kg in 2010. [3]

Yet, the progress and modernity of India have come at a cost. In parallel with the socioeconomic changes that we observe, changes in morbidity patterns have been noted. While acute illnesses, such as smallpox, leprosy, polio, and guineaworm have been controlled, chronic and metabolic diseases have become more frequent.

The prevalence of diabetes has risen markedly in India. While data from earlier decades reveals a low prevalence of type 2 diabetes in India, recent workers have reported extremely high rates of diabetes, especially in urban centers. [4],[5]

The reasons for this rise in diabetes are not difficult to find. India has become a fast-paced society, moving toward modernization and urbanization. While achieving this laudable goal, changes in dietary intake and physical activity patterns have also occurred. In India the change is more obvious among urban residents, who consume 32% of energy from fat as compared with 17% in rural residents. [6] In the past decade, motor vehicle ownership has increased by 11% annually. [7]

These factors, along with increased stress, have contributed to the increase in prevalence of diabetes. Psychosocial stress, depression, and short sleeping hours, which have become increasingly common in developing countries undergoing rapid economic developments, have been associated with higher risk of the metabolic syndrome and diabetes in Asian populations. [8]

The effect of stress on the endocrine system, including glucose metabolism, is well known. While acute stress may be beneficial in some cases, chronic or sustained stress may cause insulin resistance and hyperglycemia. [9]

Stress, therefore, should be a focus of attention while managing diabetes. Although the Ominous Octet theory of de Fronzo [10] includes various traditional and novel pathophysiologic mechanisms of diabetes, stress seems to have been forgotten. The role of dopamine as the forgotten felon of diabetes has been highlighted earlier. [11]

Nowhere is this more appropriate than in a transitional society, such as that of modern India. Within the central nervous system, dopamine is the most prevalent catecholamine. [12] Tonic stimulation of dopamine is a physiological mechanism for animals to survive the stress of migration or wintering. Sustained or tonic stimulation of the dopaminergic system, on the other hand, is harmful, and may lead to insulin resistance and hyperglycemia.

In modern India, we seem to be living in a highly charged, or sustained hyperdopaminergic state. [13] While this hyperadrenergic or hypercatecholaminergic state is helpful in achieving progress, it does have its demerits. One of them may be the Indian epidemic of diabetes mellitus.

In such a situation, the availability of a dopamine modulating antidiabetic drug, with proven efficacy and cardiovascular safety is a welcome development. Timed release bromocriptine is a novel preparation of a time-tested drug, approved by the USFDA, in 2009, for the therapy of type 2 diabetes mellitus. [11] This is the first drug to be approved by the organization after it laid down stringent requirements for demonstration of cardiovascular safety of antidiabetic drugs.

Bromocriptine is prescribed once daily, early morning, in an initial dose of 0.8 mg/day, as monotherapy, or in combination with other oral drugs. Clinical utility should be maximal in obese, depressed (anhedonic) patients with limited mobility and features of insulin resistance for the therapy of type 2 diabetes mellitus. [12],[13]

A detailed review by Shivaprasad et al., in this issue of IJEM, [14] describes the basic and clinical pharmacology of bromocriptine. An original article contributed by Ramteke et al., in this issue, provides evidence of the benefit of this molecule in a clinical trial setting in India. [15] A large multicentric postmarketing study is underway to assess the efficacy, safety, and tolerability of bromocriptine in Indian patients.

Data from this study, and from clinical experience, will provide useful information about the utility of this promising molecule.

 
   References Top

1.Available from: http://www.census.gov/ipc/prod/ib-9701.pdf. [Last accessed on 2011 Jun 24].  Back to cited text no. 1
    
2.Available from: http://www.indexmundi.com/india/life_expectancy_at_birth.html. [Last accessed on 2011 Jun 24].  Back to cited text no. 2
    
3.Available from: http://manomayam.blogspot.com/2010/07/ideal-reference-weight-for-indian-man.html. [Last accessed on 2011 Jun 24].   Back to cited text no. 3
    
4.Ramachandran A. Epidemiology of diabetes in India: Three decades of research. J Assoc Physicians India 2005;53:34-8.   Back to cited text no. 4
    
5.Ramachandran A, Mary S, Yamuna A, Murugesan N, Snehalatha C. High prevalence of diabetes and cardiovascular risk factors associated with urbanization in India. Diabetes Care 2008;31:893-8.  Back to cited text no. 5
    
6.Shetty PS. Nutrition transition in India. Public Health Nutr 2002;5:175-82.  Back to cited text no. 6
    
7.Siegel K, Narayan KM, Kinra S. Finding a policy solution to India′s diabetes epidemic. Health Aff (Millwood) 2008;27:1077-90.  Back to cited text no. 7
    
8.Chan JC, Malik V, Jia W, Kadowaki T, Yajnik CS, Yoon KH, et al. Diabetes in Asia: Epidemiology, Risk Factors, and Pathophysiology. JAMA 2009;301:2129-40.  Back to cited text no. 8
    
9.Mitra A. Diabetes and stress: A review. Ethnomedicine 2008;2:131-5.  Back to cited text no. 9
    
10.Defronzo RA. From the triumvirate to the ominous octet: A new paradigm for the treatment of type 2 diabetes mellitus. Diabetes 2009;58:773-95.  Back to cited text no. 10
    
11.Kalra S, Kalra B, Agrawal N, Kumar S. Dopamine: The forgotten felon in type 2 diabetes. Recent Pat Endocr Metab Immune Drug Discov 2011;5:61-5.  Back to cited text no. 11
    
12.Kalra S. Dopamine: The new frontier in type 2 diabetes. Int J Clin Cases Investig 2010;1:2.  Back to cited text no. 12
    
13.Kalra S. Bromocriptine: A revolution in diabetes care? Int J Clin Cases Investig 2010;1:2.  Back to cited text no. 13
    
14.Shivaprasad C, Kalra S. Bromocriptine in type 2 diabetes mellitus. Indian J Endocrinol Metab 2011;15:S17-S24.   Back to cited text no. 14
    
15.Ramteke KB, Ramanand SJ, Ramanand JB, Jain SS, Raparti GT, Patwardhan MH, et al. Evaluation of the efficacy and safety of bromocriptine QR in type 2 diabetes. Ind J Endocrinol Metab 2011;15:S33-S39.  Back to cited text no. 15
    




 

Top
 
  Search
 
    Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
    Access Statistics
    Email Alert *
    Add to My List *
* Registration required (free)  

 
  In this article
    References

 Article Access Statistics
    Viewed1495    
    Printed55    
    Emailed0    
    PDF Downloaded291    
    Comments [Add]    

Recommend this journal